Clene Inc. (NASDAQ:CLNNW) Short Interest Down 49.3% in October

Clene Inc. (NASDAQ:CLNNW) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the October 15th total of 7,100 shares. Based on an average trading volume of 6,700 shares, the short-interest ratio is currently 0.5 days.

Clene Price Performance

Shares of NASDAQ:CLNNW traded down $0.00 during trading on Wednesday, hitting $0.05. 2,331 shares of the stock were exchanged, compared to its average volume of 10,895. Clene has a 12-month low of $0.02 and a 12-month high of $0.09. The company has a fifty day moving average price of $0.04 and a two-hundred day moving average price of $0.04.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.